• WST-8 Glucose Uptake Assay: NAFLD Workflow

  2026-09-11

  Build a non-radioactive glucose uptake assay around 2-deoxyglucose processing, with practical controls for insulin-resistance and hepatic-steatosis models. This workflow connects the WST-8 readout to the Galectin-1–FIP200 findings while showing how to troubleshoot redox, cell-density, and plate effects.

• ACE2, Diminazene Aceturate, and Septic Cardiomyopathy

  2026-09-11

  The reference study identifies ACE2 downregulation as a feature of sepsis-induced cardiomyopathy and shows that pharmacological ACE2 activation with diminazene aceturate protects the septic heart in mice. Its central mechanistic contribution is linking ACE2 to Mas receptor–Sirt1 signaling and mitochondrial biogenesis, while the experimental design provides a useful framework for separating cardiac function, inflammation, oxidative stress, apoptosis, and mitochondrial endpoints.

• PVC Biofilm and Antimicrobial Resistance in VAP

  2026-09-10

  The reference study combined atomic force microscopy with susceptibility and kill-kinetic testing to show how biofilm maturation on poly(vinyl chloride) endotracheal tubes changes bacterial surface structure and reduces antimicrobial efficacy. Its comparison of ceftazidime with Hexetidine demonstrates why biofilm age and growth mode must be reported when evaluating interventions for ventilator-associated pneumonia.

• Epmedin C Protects Chicken Macrophages from DON

  2026-09-10

  The reference study identifies a ROS–caspase-1/IL-1β axis as a central component of low-dose deoxynivalenol immunotoxicity in chicken macrophages and shows that epmedin C can interrupt this response. By combining cell experiments, computational target prediction, coculture assays, and chick validation, the work provides a mechanistic basis for evaluating epmedin C as a natural mycotoxin-mitigation strategy.

• E. coli Uracil-DNA Glycosylase (UDG) Guide

  2026-09-09

  E. coli Uracil-DNA Glycosylase (UDG), SKU K1107, removes uracil from single- and double-stranded DNA and supports PCR product contamination elimination. It is intended for research workflows involving DNA, not RNA, oligonucleotides shorter than six bases, or diagnostic and medical applications.

• Drug Repurposing for CRISPR DNA Repair Control

  2026-09-09

  Macak, Kanis, and Riesenberg report a large-scale screen of FDA-approved drug conditions to identify chemical and genetic factors that redirect CRISPR-induced double-strand break repair toward NHEJ, MMEJ, or HDR. The study offers a practical framework for improving editing outcomes, modeling disease alleles, and identifying synthetic-lethal vulnerabilities, while also highlighting the need for validation across cell types, loci, and treatment contexts.

• Hepatic sEH–Nrf2 Signaling in Osteoporosis

  2026-09-08

  The reference study identifies a liver–bone axis in which hepatic soluble epoxide hydrolase alters circulating epoxyeicosatrienoic acid metabolites and inflammatory signals, thereby suppressing Nrf2-ARE activity and promoting osteoclast differentiation. Its combination of clinical observations, ovariectomy-induced osteoporosis, liver-specific gene manipulation, metabolite analysis, and transcriptomics provides a mechanistic framework for studying redox imbalance in bone disease.

• QPRT, P2Y11 Signaling, and Breast Cancer Invasion

  2026-09-08

  Liu et al. identify quinolinate phosphoribosyltransferase (QPRT) as a contributor to breast cancer invasiveness and connect its activity to myosin light chain phosphorylation through a purinergic signaling axis. The study combines genetic manipulation with pathway-directed inhibitors, providing a mechanistic framework while leaving direct P2Y11 receptor activation and clinical translation unresolved.

• G007-LK Tankyrase 1/2 Inhibitor Workflow

  2026-09-07

  Build reproducible Wnt/β-catenin and Hippo pathway experiments with G007-LK, from cell-based dose finding to mechanistic protein readouts. This workflow distinguishes APC-mutant colorectal cancer applications from the reference-supported YAP response in hepatocellular carcinoma models.

• Captopril as an ACE–Bradykinin Assay Probe

  2026-09-07

  Captopril is a powerful ACE inhibitor for hypertension research, but its experimental value extends to mechanistic studies of bradykinin-dependent physiology. This guide shows how to distinguish upstream ACE perturbation from downstream B2-receptor effects using an interpretable guinea pig ileum assay framework.

• Dabigatran etexilate Research Workflows

  2026-09-05

  Dabigatran etexilate enables a practical bridge from thrombin target engagement to plasma clotting and platelet-function assays. This guide shows how to handle its prodrug chemistry, select fit-for-purpose readouts, and troubleshoot the matrix, solubility, and conversion variables that often obscure anticoagulant activity.

• FXR LLPS Organizes Coronavirus Replication Organelles

  2026-09-04

  Li et al. show that fragile X–related proteins organize β-coronavirus double-membrane vesicles through liquid–liquid phase separation, linking condensate biology to replication-organelle architecture. The study identifies FXR-dependent DMV clustering as a host process that supports translation near viral replication sites and efficient SARS-CoV-2 replication.

• Quizartinib (AC220) in FLT3 AML Workflows

  2026-09-04

  Quizartinib (AC220) combines low-nanomolar FLT3 potency with selectivity that supports cleaner pathway attribution in acute myeloid leukemia (AML) research. This guide converts that profile into practical phosphorylation, viability, resistance, and xenograft workflows, with assay controls designed to separate on-target biology from handling artifacts.

• AmpliFold Capture-and-Release for Sensitive LFAs

  2026-09-03

  The AmpliFold strategy addresses a central lateral flow assay bottleneck by separating initial analyte capture from final signal detection. In a HER2 model, triggered release and high-affinity rebinding improved sensitivity while retaining a rapid, equipment-free workflow, although additional validation is needed before general clinical translation.

• Redox-Responsive Peptide Coacervates for mRNA Delivery

  2026-09-03

  Ren and colleagues developed HBpep-SS4, a single-component peptide coacervate that combines high mRNA encapsulation with glutathione-triggered intracellular release. The study shows broad RNA cargo compatibility, efficient cellular delivery, and functional genome editing, while also defining important limitations for translation beyond the tested models.

8084 records 1/539 page Next 12345 下5页 Last page